Martin Reck - Researcher Profile | RDL Research Database

Publications

3 shown

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

Mark A. Socinski , Robert M. Jotte , Federico Cappuzzo +17 more

The addition of atezolizumab to bevacizumab plus chemotherapy significantly improved progression-free survival and overall survival among patients with metastatic nonsquamous NS...

2018 New England Journal of Medicine 3592 citations

Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer

Leena Gandhi , Delvys Rodríguez‐Abreu , Shirish M. Gadgeel +26 more

In patients with previously untreated metastatic nonsquamous NSCLC without EGFR or ALK mutations, the addition of pembrolizumab to standard chemotherapy of pemetrexed and a plat...

2018 New England Journal of Medicine 6245 citations

Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial

Martin Reck , R. Kaiser , Anders Mellemgaard +11 more

2014 The Lancet Oncology 923 citations

Frequent Co-Authors

Researcher Info

h-index: 3
Publications: 3
Citations: 10,760
Institution: German Center for Lung Research

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0002-5348-4462

Impact Metrics

h-index 3

h-index: Number of publications with at least h citations each.